SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of November 2018

Commission File Number 000-31062

Oncolytics Biotech Inc.

(Translation of registrant's name into English)

Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☑ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

INCORPORATION BY REFERENCE

The Registrant's Management's Discussion and Analysis of Operations and Financial Condition for the Three and Nine Months Ended September 30, 2018, included as Exhibit 99.2 of this Form 6-K and the Interim Financial Statements as of and for the Three and Nine Months Ended September 30, 2018, included as Exhibit 99.1 of this Form 6-K (Commission File No. 001-31062), furnished to the Commission on November 12, 2018, are incorporated by reference into the Registrant's Registration Statement on Form F-10 (Commission File No. 333-224432).

EXHIBIT NUMBER	DESCRIPTION
99.1	Oncolytics Biotech® Inc. September 30, 2018 Interim Financial Statements
99.2	Oncolytics Biotech® Inc. September 30, 2018 Management Discussion & Analysis
99.3	Certification of September 30, 2018 interim filings - CEO
99.4	Certification of September 30, 2018 interim filings - CFO

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Oncolytics Biotech Inc.
(Registrant)

By: /s/ *Kirk Look*

Kirk Look
Chief Financial Officer

Date: November 12, 2018

Interim Consolidated Financial Statements
(unaudited)

Oncolytics Biotech® Inc.
September 30, 2018 and 2017

ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(unaudited)

As at	Notes	September 30, 2018 $	December 31, 2017 $
Assets			
Current assets			
Cash and cash equivalents	*4*	**16,214,347**	11,836,119
Contract receivable	*8*	**—**	4,767,100
Other receivables		**56,895**	37,726
Prepaid expenses		**1,450,030**	1,176,063
Total current assets		**17,721,272**	17,817,008
Non-current assets			
Property and equipment		**428,588**	333,441
Total non-current assets		**428,588**	333,441
Total assets		**18,149,860**	18,150,449
Liabilities And Shareholders' Equity			
Current Liabilities			
Accounts payable and accrued liabilities		**2,239,514**	3,684,023
Contract liability	*8*	**927,400**	1,545,645
Other liabilities	*9*	**76,529**	—
Total current liabilities		**3,243,443**	5,229,668
Non-current liabilities			
Contract liability	*8*	**5,802,887**	4,636,935
Other liabilities	*9*	**54,128**	—
Total non-current liabilities		**5,857,015**	4,636,935
Total liabilities		**9,100,458**	9,866,603
Commitments and contingencies	*9*		
Shareholders' equity			
Share capital Authorized: unlimited Issued: September 30, 2018 – 16,915,325 December 31, 2017 – 141,805,722 pre-consolidation December 31, 2017 – 14,926,840 post-consolidation	*5*	**283,742,409**	271,710,138
Warrants	*5*	**3,617,570**	3,617,900
Contributed surplus	*6*	**27,894,420**	27,028,238
Accumulated other comprehensive income		**459,142**	373,730
Accumulated deficit		**(306,664,139)**	(294,446,160)
Total shareholders' equity		**9,049,402**	8,283,846
Total liabilities and equity		**18,149,860**	18,150,449

See accompanying notes

ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(unaudited)

	Notes	Three Month Period Ending September 30, 2018 $	Three Month Period Ending September 30, 2017 $	Nine Month Period Ending September 30, 2018 $	Nine Month Period Ending September 30, 2017 $
Expenses					
Research and development	*6, 13, 14*	**1,929,405**	1,726,726	**6,909,713**	6,913,470
Operating	*6, 13, 14*	**1,468,262**	1,309,607	**4,869,617**	4,054,450
Loss before the following		**(3,397,667)**	(3,036,333)	**(11,779,330)**	(10,967,920)
Interest		**61,880**	31,759	**109,308**	96,637
Loss before income taxes		**(3,335,787)**	(3,004,574)	**(11,670,022)**	(10,871,283)
Income tax (expense) recovery		**(79)**	168	**(547,957)**	16
Net loss		**(3,335,866)**	(3,004,406)	**(12,217,979)**	(10,871,267)
Other comprehensive (loss) income items that may be reclassified to net loss					
Translation adjustment		**(49,238)**	(126,846)	**85,412**	(192,334)
Net comprehensive loss		**(3,385,104)**	(3,131,252)	**(12,132,567)**	(11,063,601)
Basic and diluted loss per common share	*7*	**(0.20)**	(0.20)	**(0.78)**	(0.80)
Weighted average number of shares (basic and diluted)	*7*	**16,540,612**	14,685,871	**15,646,117**	13,625,411

See accompanying notes

ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(unaudited)

	Notes	Share Capital $	Warrants $	Contributed Surplus $	Accumulated Other Comprehensive Income $	Accumulated Deficit $	Total $
As at December 31, 2016		262,321,825	—	26,643,044	554,060	(278,829,309)	10,689,620
Net loss and other comprehensive loss		—	—	—	(192,334)	(10,871,267)	(11,063,601)
Issued pursuant to "At the Market" agreement	*5*	1,479,065	—	—	—	—	1,479,065
Issued pursuant to public offering	*5*	7,893,600	3,617,900	—	—	—	11,511,500
Issued pursuant to stock option plan	*6*	536,949	—	(193,509)	—	—	343,440
Share based compensation	*6*	—	—	438,044	—	—	438,044
Share issue costs	*5*	(1,331,770)	—	—	—	—	(1,331,770)
As at September 30, 2017		270,899,669	3,617,900	26,887,579	361,726	(289,700,576)	12,066,298
As at December 31, 2017		271,710,138	3,617,900	27,028,238	373,730	(294,446,160)	8,283,846
Net loss and other comprehensive income		—	—	—	85,412	(12,217,979)	(12,132,567)
Issued pursuant to "At the Market" agreement	*5*	553,650	—	—	—	—	553,650
Issued pursuant to public offering	*5*	11,606,882	—	—	—	—	11,606,882
Issued pursuant to Common Stock Purchase Agreement	*5*	1,906,152	—	—	—	—	1,906,152
Issued pursuant to stock option plan	*6*	178,322	—	(66,635)	—	—	111,687
Issued pursuant to warrant agreement	*5*	1,747	(330)	—	—	—	1,417
Share based compensation	*6*	—	—	932,817	—	—	932,817
Share issue costs	*5*	(2,214,482)	—	—	—	—	(2,214,482)
As at September 30, 2018		**283,742,409**	**3,617,570**	**27,894,420**	**459,142**	**(306,664,139)**	**9,049,402**

See accompanying notes

ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

	Notes	Three Month Period Ending September 30, 2018 $	Three Month Period Ending September 30, 2017 $	Nine Month Period Ending September 30, 2018 $	Nine Month Period Ending September 30, 2017 $
Operating Activities					
Net loss for the period		**(3,335,866)**	(3,004,406)	**(12,217,979)**	(10,871,267)
Depreciation - property and equipment	*13*	**26,698**	20,591	**67,682**	70,315
Share based compensation	*6, 13, 14*	**236,607**	148,447	**932,817**	438,044
Unrealized foreign exchange loss (gain)		**82,643**	(6,414)	**(19,702)**	(119,058)
Onerous lease contract	*9, 13*	**67,588**	—	**67,588**	—
Amortization - lease incentive liability	*9, 13*	**12,494**	—	**12,494**	—
Net change in non-cash working capital	*12*	**(596,779)**	(331,590)	**3,630,991**	(1,186,142)
Cash used in operating activities		**(3,506,615)**	(3,173,372)	**(7,526,109)**	(11,668,108)
Investing Activities					
Acquisition of property and equipment		**(40,094)**	(9,451)	**(120,156)**	(95,337)
Redemption of short-term investments		**—**	—	**—**	2,088,800
Cash (used in) provided by investing activities		**(40,094)**	(9,451)	**(120,156)**	1,993,463
Financing Activities					
Proceeds from "At the Market" equity distribution agreement	*5*	**—**	733,171	**520,315**	1,292,698
Proceeds from public offering	*5*	**—**	—	**10,188,526**	10,366,098
Proceeds from Common Stock Purchase Agreement	*5*	**1,143,361**	—	**1,143,361**	—
Proceeds from exercise of options	*6*	**87,777**	48,090	**111,687**	343,440
Proceeds from exercise of warrants	*5*	**—**	—	**1,417**	—
Cash provided by financing activities		**1,231,138**	781,261	**11,965,306**	12,002,236
(Decrease) increase in cash		**(2,315,571)**	(2,401,562)	**4,319,041**	2,327,591
Cash and cash equivalents, beginning of period		**18,741,347**	16,676,298	**11,836,119**	12,034,282
Impact of foreign exchange on cash and cash equivalents		**(211,429)**	(241,092)	**59,187**	(328,229)
Cash and cash equivalents, end of period		**16,214,347**	14,033,644	**16,214,347**	14,033,644

See accompanying notes

Note 1: Incorporation and Nature of Operations

Oncolytics Biotech Inc. was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc.

Our interim consolidated financial statements for the period ended September 30, 2018, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on November 8, 2018. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded and our registered office is located at 210, 1167 Kensington Crescent NW, Calgary, Alberta, Canada.

We are a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers that have not been successfully treated with conventional therapeutics. Our lead product, pelareorep, is a potential immuno-oncology viral-agent that may be a novel treatment for certain types of cancer and may be an alternative to existing cytotoxic or cytostatic therapies. Our clinical development program for pelareorep emphasizes three programs: chemotherapy combinations to assist the escape of the virus from the vasculature and enhance its distribution in the tumor; immuno-therapy combinations to create an inflamed phenotype promoting synergies with immune checkpoint inhibitors; and immune modulator/targeted combinations to upregulate natural killer cells promoting synergies with targeted therapies.

Note 2: Basis of Financial Statement Presentation

Our interim consolidated financial statements include our financial statements and the financial statements of our subsidiaries as at September 30, 2018 and are presented in Canadian dollars, our functional currency.

Our accounts are prepared in accordance with International Financial Reporting Standards ("IFRS") issued by the International Accounting Standards Board ("IASB"). The accounts are prepared on the historical cost basis, except for certain assets and liabilities which are measured at fair value as explained in the notes to these financial statements.

These interim consolidated financial statements have been prepared in compliance with International Accounting Standard 34 *Interim Financial Reporting.* The notes presented in these interim consolidated financial statements include only significant events and transactions occurring since our last fiscal year end and are not fully inclusive of all matters required to be disclosed in our annual audited consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with our most recent annual audited consolidated financial statements, for the year ended December 31, 2017. We have consistently applied the same accounting policies for all periods presented in these interim consolidated financial statements as those used in our audited consolidated financial statements for the year ended December 31, 2017, except for the adoption of new standards effective as of January 1, 2018.

Note 3: Significant Accounting Policies

Adoption of New Accounting Standards

IFRS 9 *Financial Instruments*
IFRS 9 *Financial Instruments* ("IFRS 9") replaces IAS 39 *Financial Instruments: Recognition and Measurement* for annual periods beginning on or after January 1, 2018. IFRS 9 includes guidance on the classification and measurement of financial assets and financial liabilities and impairment of financial assets.

We have applied IFRS 9 retrospectively, with the initial application date of January 1, 2018. There were no changes to the measurement of our financial assets and liabilities or adjustments to comparative information as a result of the adoption of IFRS 9.

(a) Classification and measurement

Financial assets
Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs.

Under IFRS 9, financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company's business model for managing the assets; and whether the financial asset's contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion').

Our financial assets include cash and cash equivalents and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. Under IAS 39, our financial assets were classified as follows: cash and cash equivalents - held for trading and other receivables - loans and receivables. The accounting for our financial assets remained the same as it was under IAS 39.

Financial liabilities
Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost. The accounting for our financial liabilities remained the same as it was under IAS 39.

(b) Impairment

Under IFRS 9, accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach.

IFRS 9 requires that we record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset's original effective interest rate.

We have applied the simplified approach permitted by IFRS 9 and calculated ECLs based on lifetime expected credit losses. We have established a provision matrix that is based on historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

There were no adjustments in impairment allowances of our financial assets as a result of the adoption of the ECL requirements of IFRS 9.

Accounting Standards Issued but Not Yet Effective

IFRS 16 *Leases*
In January 2016, the IASB issued IFRS 16 *Leases* ("IFRS 16"), which replaces IAS 17 *Leases* and related interpretations. IFRS 16 provides a single lessee accounting model, requiring the recognition of assets and liabilities for all leases, unless the lease term is 12 months or less or the underlying asset has a low value. The new standard is effective for annual periods beginning on or after January 1, 2019. We are assessing the impact of adoption of the standard on our consolidated financial statements.

Note 4: Cash Equivalents

Cash Equivalents
Cash equivalents consist of interest bearing deposits with our bank totaling $11,557,503 (December 31, 2017 – $9,204,919). The current annual interest rate earned on these deposits is 2.12% (December 31, 2017 – 1.38%).

Note 5: Share Capital

Authorized:
Unlimited number of no par value common shares

Share Consolidation:
On May 22, 2018, we completed the consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, 9.5 2017 warrants will entitle the holder to purchase one whole common share until June 1, 2022.

Issued:	Shares		Warrants	
	Number	Amount $	Number	Amount $
Balance, December 31, 2016	121,258,222	262,321,825	—	—
Issued pursuant to stock option plan	801,000	536,949	—	—
Issued pursuant to "At the Market" equity distribution agreement[a]	3,301,500	2,348,821	—	—
Issued pursuant to public offering[b]	16,445,000	7,893,600	16,445,000	3,617,900
Share issue costs	—	(1,391,057)	—	—
Balance, December 31, 2017	141,805,722	271,710,138	16,445,000	3,617,900
Issued pursuant to "At the Market" equity distribution agreement[a]	519,500	553,650	—	—
Share issue costs	—	(33,335)	—	—
Balance, March 31, 2018	142,325,222	272,230,453	16,445,000	3,617,900
Issued pursuant to stock option plan	71,000	38,269	—	—
Balance, May 22, 2018 - pre-consolidation	142,396,222	272,268,722	16,445,000	3,617,900
Balance, May 22, 2018 - post-consolidation	14,988,995	272,268,722	16,445,000	3,617,900
Issued pursuant to public offering[c]	1,532,278	11,606,882	—	—
Issued pursuant to warrant agreement[b]	157	1,747	(1,500)	(330)
Issued pursuant to stock option plan	30,119	140,053	—	—
Issued pursuant to Common Stock Purchase Agreement[d]	363,776	1,906,152	—	—
Share issue costs	—	(2,181,147)	—	—
Balance, September 30, 2018	**16,915,325**	**283,742,409**	**16,443,500**	**3,617,570**

(a) On February 25, 2016, we entered into an "at-the-market" ("ATM") equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million which allows us to sell our common shares through the facilities of the Toronto Stock Exchange or other "marketplace" (as defined in National Instrument 21-101 Marketplace Operation) in Canada (our "Canadian ATM"). Subject to the terms of our Canadian ATM, we are able to determine, at our sole discretion, the timing and number of shares to be sold under this ATM facility. During the period ending September 30, 2018, we sold 519,500 pre-consolidation shares (approximately 54,684 post-consolidation shares) (2017 - 2,167,500 pre-consolidation shares (approximately 228,157 post-consolidation shares)) for gross proceeds of $553,650 (2017 - $1,479,065). We incurred share issue costs of $33,335 (2017 - $186,367).

(b) On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold at a purchase price of $0.70 per unit for gross proceeds of $11,511,500. Each unit included one pre-consolidation common share with an ascribed value of $0.48 (0.106 post-consolidation common share with an ascribed value of $4.56) and one pre-consolidation common share purchase warrant with an ascribed value of $0.22 (one post-consolidation common share purchase warrant with an ascribed value of

$2.09). Each pre-consolidation common share purchase warrant entitled the the holder to purchase one pre-consolidation common share at an exercise price of $0.95. Following the Share Consolidation, 9.5 pre-consolidation common share purchase warrants entitles the holder to purchase one post-consolidation common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. The post-consolidation common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds $23.75 for 15 consecutive trading dates. The ascribed value was determined using the relative fair value method. The ascribed value of the common share purchase warrants was determined using the Black Scholes option pricing model. We incurred share issue costs of $1,145,402.

(c) On June 5, 2018, pursuant to an underwritten public offering, 1,532,278 common shares were sold at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356.

(d) On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$26,000,000 worth of common shares to LPC over the 30-month term. The purchase price of the common shares will be based on the prevailing market prices immediately preceding the notice of sale without any fixed discount. Subject to the terms of the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty.

Upon signing of the Agreement, LPC purchased 248,762 common shares for gross proceeds of US$1,000,000. In consideration for entering into the Agreement, we issued an initial commitment fee of 110,754 common shares to LPC valued at fair value of US$455,000. An additional 110,754 common shares will be issued on a pro rata basis under the terms of the Agreement as an additional commitment fee. We issued 4,260 additional commitment fee common shares valued at fair value of US$17,501. The initial commitment fee and additional commitment fee common shares were recorded as share issue costs in addition to cash share issue costs of $151,139.

Warrants

The following table summarizes our outstanding warrants at September 30, 2018:

Exercise Price	Outstanding, Beginning of the Period	Granted During the Period	Exercised During the Period	Outstanding, End of the Period	Weighted Average Remaining Contractual Life (years)
$ 9.025	16,445,000	—	(1,500)	16,443,500	3.67

Note 6: Share Based Payments

On May 22, 2018, we completed our Share Consolidation (see Note 5), as a result, all stock option and share award disclosures have been retrospectively adjusted to reflect the Share Consolidation.

Stock Option Plan

We have issued stock options to acquire common stock through our stock option plan of which the following are outstanding at September 30:

	2018		2017	
	Stock Options	Weighted Average Exercise Price $	Stock Options	Weighted Average Exercise Price $
Outstanding, beginning of the period	**647,156**	**13.20**	912,995	17.42
Granted during the period	**327,467**	**7.38**	31,049	4.30
Forfeited during the period	**(90,817)**	**11.74**	(73,887)	30.94
Expired during the period	—	—	(1,882)	21.38
Exercised during the period	**(37,592)**	**2.97**	(84,315)	4.07
Outstanding, end of the period	**846,214**	**11.56**	783,960	17.05
Options exercisable, end of the period	**598,222**	**13.56**	636,752	20.16

The following table summarizes information about the stock options outstanding and exercisable at September 30, 2018:

Range of Exercise Prices	Number Outstanding	Weighted Average Remaining Contractual Life (years)	Weighted Average Exercise Price $	Number Exercisable	Weighted Average Exercise Price $
$2.47 - $3.99	293,037	7.7	3.36	256,247	3.29
$4.84 - $7.81	345,932	4.1	7.19	134,730	7.13
$13.77 - $19.00	95,535	4.8	16.90	95,535	16.90
$20.23 - $36.96	53,038	3.0	32.16	53,038	32.16
$38.09 - $63.84	58,672	3.2	50.92	58,672	50.92
	846,214	5.3	11.56	598,222	13.56

Non-exercisable options vest annually over periods ranging from one to three years.

The estimated fair value of stock options issued during the period was determined using the Black Scholes Option Pricing Model using the following weighted average assumptions and fair value of options:

	2018	2017
Risk-free interest rate	**1.89%**	1.06%
Expected hold period to exercise	**3.0 years**	3.0 years
Volatility in the price of the Company's shares	**83.94%**	92.43%
Rate of forfeiture	**3.67%**	3.67%
Dividend yield	**Nil**	Nil
Weighted average fair value of options	**$4.03**	$2.52

We use historical data to estimate the expected dividend yield and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates in effect at the time of grant and the expected life of the options represents the estimated length of time the options are expected to remain outstanding.

Incentive Share Award Plan

Restricted Share Units

We have issued restricted share units ("RSUs") to non-employee directors through our incentive share award plan. Grants of RSUs to non-employee directors vest either on the third anniversary date from the grant date or when the director ceases to be a member of the board. We have also issued RSUs to certain officers and employees of the Company. Grants of RSUs to certain officers and employees of the Company vest over a three year period. The following RSUs are outstanding at September 30:

	2018	2017
Outstanding, beginning of the period	**190,407**	139,237
Granted during the period	**8,891**	21,593
Forfeited during the period	**(2,105)**	—
Outstanding, end of the period	**197,193**	160,830

(1) The weighted average fair value of the RSUs granted was $6.27 in 2018 (2017 - $5.43).

Performance Share Units

We have also issued performance share units ("PSUs") to certain officers and employees of the Company. Grants of PSUs require completion of certain performance criteria and cliff vest after 3 years or vest over a three year period, depending on the grant. PSU grants to certain officers will vest immediately upon a change of control of the Company. If certain officers cease employment with the Company, vesting occurs on a pro rata basis prior to the third anniversary of the grant but after the first anniversary. The following PSUs are outstanding at September 30:

	2018	2017
Outstanding, beginning of the period	**94,734**	88,419
Granted during the period	**—**	6,315
Forfeited during the period	**(31,578)**	—
Outstanding, end of the period	**63,156**	94,734

(1) The weighted average fair value of the PSUs granted in 2017 was $3.33.

We have reserved 1,691,533 common shares for issuance relating to our outstanding equity compensation plans. Compensation expense related to stock options, RSUs and PSUs was $236,607 and $932,817 for the three and nine month periods ending September 30, 2018, respectively (2017 - $148,447 and $438,044, respectively).

Note 7: Loss Per Common Share

Loss per common share is calculated using net loss for the year and the weighted average number of common shares outstanding for the three and nine month periods ended September 30, 2018 of 16,540,612 and 15,646,117, respectively (September 30, 2017 - 14,685,871 and 13,625,411, respectively). The effect of any potential exercise of our stock options and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.

Note 8: Contract Liability and Receivable

Regional licensing agreement
We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties and sales-based milestone payments.

Warrant purchase agreement
We also entered into a warrant purchase agreement with Adlai. Under the terms of the warrant purchase agreement, we are entitled to receive two milestone payments totaling US$8 million made up of two common share purchase warrants:

- One common share purchase warrant of US$2 million whereby, upon exercise, Adlai may purchase our common shares priced at a 20% premium to the five-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant when the first patient is enrolled in the phase 3 metastatic breast cancer study or six months after execution of the Agreement, whichever is later.
- One common share purchase warrant of US$6 million whereby, upon exercise, Adlai may purchase our common shares priced at a 20% premium to the five-day weighted average closing price immediately preceding the exercise date. We have the right to call this warrant upon the enrollment of the 50th patient in the phase 3 metastatic breast cancer study.

Contract liability
Our contract liability balance, which we expect to record in revenue over the next five years, is as follows:

	September 30, 2018 $	**December 31, 2017 $**
Balance, beginning of the period	**6,182,580**	—
Regional licensing agreement	**547,707**	6,182,580
Revenue recognized in the period	**—**	—
Balance, end of the period	**6,730,287**	6,182,580
Contract liability - current	**927,400**	1,545,645
Contract liability - non-current	**5,802,887**	4,636,935
	6,730,287	6,182,580

Contract receivable
Our contract receivable due from Adlai at September 30, 2018 is nil (December 31, 2017 - $4,767,100 (US$3,800,000)). On collection of the contract receivable, an income tax expense of $547,707 was recorded with a corresponding credit to the contract liability.

Note 9: Commitments

We are committed to payments totaling $5,850,832 for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years.

We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases. In the third quarter of 2018, we entered into a new multi-year lease agreement which provided for lease incentives of $77,911 to be recognized over the lease term. We also recorded an onerous lease provision related to the old lease of $67,588 as a result of this lease agreement. Annual payments under the terms of our office leases are as follows:

	Amount $
Remainder of 2018	100,875
2019	407,020
2020	357,432
2021	160,268
	1,025,595

Under a clinical trial agreement entered into with the Alberta Cancer Board ("ACB"), we have agreed to repay the amount funded under the agreement together with a royalty, to a combined maximum amount of $400,000 plus an overhead repayment of $100,000, upon sales of a specified product. We agreed to repay the ACB in annual installments in an amount equal to the lesser of: (a) 5% of gross sales of a specified product; or (b) $100,000 per annum once sales of a specified product commence.

Note 10: Capital Disclosures

Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs and intellectual property expansion and protection. We include shareholders' equity and cash and cash equivalents in the definition of capital.

	September 30, 2018 $	**December 31, 2017 $**
Cash and cash equivalents	**16,214,347**	11,836,119
Shareholders' equity	**9,049,402**	8,283,846

We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of pelareorep.

In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year's activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.

Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares. Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital. There are no assurances that funds will be made available to us when required.

On May 4, 2018, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may

sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.

Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until May 25, 2020.

Our Base Shelf allowed us to enter into our Common Stock Purchase Agreement in the third quarter of 2018 (see Note 5) and our ATM equity offering sales agreement in October 2018 (see Note 15). We will use these equity arrangements to assist us in achieving our capital objective. Each arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources.

We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2018.

Note 11: Financial Instruments

Our financial instruments consist of cash and cash equivalents, other receivables and accounts payable. As at September 30, 2018, there are no significant differences between the carrying values of these amounts and their estimated market values.

Credit risk
Credit risk is the risk of financial loss if a counterparty to a financial instrument fails to meet its contractual obligations. We are exposed to credit risk on our cash and cash equivalents and contract receivable in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and contract receivable.

We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada. For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.

Interest rate risk
Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates. We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments. We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.

Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.

Currency risk
Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from operating and financing activities. As well, we are exposed to currency risk related to our regional licensing agreement. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net loss in 2018 by approximately $54,035. The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net loss in 2018 by approximately $21,923. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net loss in 2018 by approximately $8,978.

We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.

Balances in foreign currencies at September 30, 2018 are as follows:

	US dollars $	British pounds £	Euro €
Cash and cash equivalents	11,123,553	23,827	24,246
Accounts payable	(430,913)	(46,510)	—
	10,692,640	(22,683)	24,246

Liquidity risk
Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in Note 10. Accounts payable are all due within the current operating period.

Note 12: Additional Cash Flow Disclosures

Net Change In Non-Cash Working Capital

	Three Month Period Ending September 30, 2018 $	Three Month Period Ending September 30, 2017 $	Nine Month Period Ending September 30, 2018 $	Nine Month Period Ending September 30, 2017 $
Change in:				
Contract receivable	**—**	—	**4,767,100**	—
Other receivables	**32,819**	28,980	**(19,169)**	21,277
Prepaid expenses	**39,182**	46,925	**(273,967)**	(177,309)
Accounts payable and accrued liabilities	**(799,407)**	(529,016)	**(1,486,992)**	(1,286,732)
Contract liability	**—**	—	**547,707**	—
Other liabilities	**50,575**	—	**50,575**	**—**
Non-cash impact of foreign exchange	**80,052**	121,521	**45,737**	256,622
Change in non-cash working capital related to operating activities	**(596,779)**	(331,590)	**3,630,991**	(1,186,142)

Other Cash Flow Disclosures

	Three Month Period Ending September 30, 2018 $	Three Month Period Ending September 30, 2017 $	Nine Month Period Ending September 30, 2018 $	Nine Month Period Ending September 30, 2017 $
Cash interest received	**61,880**	31,759	**109,308**	96,637
Cash taxes paid	**—**	**—**	**3,752**	—

Note 13: Other Expenses and Adjustments

We present our expenses based on the function of each expense and therefore include realized foreign exchange gains and losses, unrealized non-cash foreign exchange gains and losses and non-cash stock based compensation associated with research and development activity as a component of research and development expenses and amortization of property and equipment and stock based compensation associated with operating activities as a component of operating expenses.

	Three Month Period Ending September 30, 2018 $	Three Month Period Ending September 30, 2017 $	Nine Month Period Ending September 30, 2018 $	Nine Month Period Ending September 30, 2017 $
Included in research and development expenses:				
Realized foreign exchange loss (gain)	**43,104**	(40,097)	**(4,401)**	(40,141)
Unrealized non-cash foreign exchange loss (gain)	**131,882**	(88,738)	**(105,114)**	(135,894)
Non-cash share based compensation	**107,960**	56,757	**438,469**	182,860
Included in operating expenses				
Depreciation - property and equipment	**26,698**	20,591	**67,682**	70,315
Non-cash share based compensation	**128,647**	91,690	**494,348**	255,184
Office minimum lease payments	**73,672**	65,186	**220,988**	163,324
Onerous lease contract	**67,588**	—	**67,588**	—
Amortization - lease incentive liability	**12,494**	—	**12,494**	—

Note 14: Related Party Transactions

Compensation of Key Management Personnel

Key management personnel are those persons having authority and responsibility for planning, directing and controlling our activities as a whole. We have determined that key management personnel consists of the members of the Board of Directors along with certain officers of the Company.

	Three Month Period Ending September 30, 2018 $	Three Month Period Ending September 30, 2017 $	Nine Month Period Ending September 30, 2018 $	Nine Month Period Ending September 30, 2017 $
Short-term employee compensation and benefits	**399,855**	477,800	**1,356,410**	1,588,602
Termination benefits	**—**	—	**—**	779,666
Share-based payments	**185,643**	128,161	**672,325**	339,824
	585,498	605,961	**2,028,735**	2,708,092

Assumption Agreement

In November 2017, with the signing of a regional licensing agreement with upfront license fees (see Note 8), the Company triggered a liability of US$178,125 to an officer as detailed in the Assumption Agreement (see Note 12 of our audited consolidated financial statements for the year ended December 31, 2017). As at September 30, 2018, the liability was fully paid.

Note 15: Subsequent Event

On October 24, 2018, we entered into an ATM equity offering sales agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30,000,000 over the next 19 months through the facilities of the NASDAQ in the United States.

MANAGEMENT DISCUSSION & ANALYSIS

September 30, 2018

November 8, 2018

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This discussion and analysis should be read in conjunction with the unaudited interim consolidated financial statements of Oncolytics Biotech® Inc. as at and for the three and nine months ended September 30, 2018 and 2017, and and should also be read in conjunction with the audited consolidated financial statements and Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") contained in our annual report for the year ended December 31, 2017. The financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS").

FORWARD-LOOKING STATEMENTS

The following discussion contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and under applicable Canadian provincial securities legislation. Forward-looking statements, including our belief as to the potential of pelareorep, an intravenously delivered immuno-oncolytic virus, as a cancer therapeutic and our expectations as to the success of our research and development, clinical and manufacturing programs in 2018 and beyond, future financial position, business strategy and plans for future operations, and statements that are not historical facts, involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements.

Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process and general changes to the economic environment.

With respect to the forward-looking statements made within this MD&A, we have made numerous assumptions regarding among other things: our ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep and future expense levels being within our current expectations.

Investors should consult our quarterly and annual filings with the Canadian and US securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and/or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake to update these forward-looking statements except as required by applicable law.

Pelareorep Development Update For 2018

Oncolytics Biotech Inc. is a Development Stage Company

Since our inception in April of 1998, Oncolytics Biotech Inc. has been a development stage company. We have focused our research and development efforts on the development of pelareorep, an intravenously delivered immuno-oncolytic virus (IOV) with the potential to treat a variety of cancers. We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until, and unless, pelareorep becomes commercially viable.

Our goal each year is to advance pelareorep through the various steps and stages of development required for potential pharmaceutical products. In order to achieve this goal, we believe that we have to actively manage the development of our clinical trial program, our pre-clinical and collaborative programs, our manufacturing process and pelareorep supply, and our intellectual property.

Clinical Trial Program

Our clinical development plan, based on drug combinations that can potentially boost each response of the mechanism of action, has two main objectives. The primary objective is to obtain regulatory approval for pelareorep as quickly as possible and is based on the compelling metastatic breast cancer survival data that was presented at the 2017 American Association for Cancer Research (AACR) Annual Meeting, in Washington, D.C. The second objective is to expand pelareorep into commercially valuable new treatment areas that include immunotherapy and immunomodulatory (IMiD) agents in collaboration with pharmaceutical partners.

Third Quarter 2018 Developments

Master Clinical Supply Agreement with F. Hoffmann-La Roche Ltd (Roche)

In September 2018, we entered into a five-year Master Clinical Supply Agreement with Roche, where Roche will supply its anti-PD-L1 checkpoint inhibitor, atezolizumab (Tecentriq®), for use in our clinical development program.

Metastatic Breast Cancer - Registration Study

In 2017, we reported a statistically significant increase of 7 months (10.4 months to 17.4 months) in median overall survival from an open-label, randomized phase 2 metastatic breast cancer (mBC) study of intravenously-administered pelareorep given in combination with the chemotherapy agent paclitaxel. Pelareorep was awarded fast track designation by the United States Food and Drug Administration (FDA) for the treatment of mBC. We announced a productive End-of-Phase 2 meeting with the FDA for pelareorep in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients. The purpose of the meeting was to discuss the preclinical and clinical programs, including the design of the phase 3 registration study to support a future Biologics License Application (BLA) submission in the U.S. We also received a supportive Final Advice Letter from the European Medicines Agency (EMA) suggesting that a phase 3 study may be acceptable to form the basis of a Marketing Authorization Application (MAA) in Europe for the proposed use of pelareorep in combination with paclitaxel for the treatment of HR+/HER2- mBC. As a result of our statistically significant phase 2 data supported by a fast track designation, productive End-of-Phase 2 meeting with the FDA and supportive Final Advice Letter from the EMA, our objective is to advance pelareorep in combination with paclitaxel, into a phase 3 registration study for the treatment of HR+/HER2- mBC.

As part of the preparations for initiation of our phase 3 registration study, we announced a collaboration with SOLTI, an academic research group dedicated to clinical and translational research in breast cancer. This clinical collaboration is a window of opportunity study in the neoadjuvant setting for breast cancer using pelareorep in combination with Roche's Tecentriq®. Data generated from this study is intended to confirm that the virus is acting as a novel immunotherapy and to provide comprehensive biomarker data by breast cancer sub-type to support our phase 3 study in metastatic breast cancer. The goal of this study is to supplement the existing randomized phase 2 results by providing key data points to enhance our chance of success in the phase 3 registration study. The results of this study may also provide an opportunity to add a checkpoint inhibitor arm to the phase 3 study.

Other immunotherapy combinations

In support of the adaptive immunity component of pelareorep's mechanism of action, we further expanded our immunotherapy combinations. In September 2018, we announced a checkpoint inhibitor study, which uses pelareorep in combination with Bristol-Myers Squibb's anti-PD1 checkpoint inhibitor Opdivo®. This is an investigator sponsored study facilitated by Emory University and the University of Utah and will evaluate the safety in relapsed or refractory myeloma patients and measure the development of a pro-inflammatory phenotype in the tumor microenvironment. Once the safety of the initial combination is demonstrated, Celgene Corporation's immunodulatory drug Pomalyst® may be added to the treatment regimen.

Post Third Quarter 2018 Development

In October 2018, we announced final clinical trial results for pelareorep in the treatment of patients with KRAS mutant metastatic colorectal cancer. The following poster was presented:

Title	Presenter	Location	Description/Conclusion
Dose finding and safety study of Reovirus (Reo) with irinotecan/fluorouracil/leucovorin/bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC): Final Results	Dr. Sanjay Goel, M.D., Department of Medical Oncology, Montefiore Medical Centre.	European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany	Highlights in the poster include: – Of the six patients receiving the recommended phase 2 dose (RPTD), three had a partial response (50%) and the median progression free survival (PFS) and overall survival (OS) were 65.6 weeks and 107.5 weeks, respectively, exceeding expectations when compared to historical data – Reovirus administration is marked by activation of cytotoxic T-cells and rapid maturation of dendritic cells – Reovirus is safe and well tolerated in combination with FOLFIRI and Bevacizumab

Manufacturing and Process Development

During the third quarter of 2018, we supplied our clinical development program with previously filled product from our existing supply of pelareorep, labeled for the applicable usage and in line with extended stability data. As well, we continued our activities to develop clinical and commercial production capabilities to fill pelareorep into vials, the next step in the process validation master plan. Process validation is required to ensure that the resulting product meets required specifications and quality standards and will form part of the Company's submission to regulators, including the FDA, for product approval.

Intellectual Property

At the end of the third quarter of 2018, we had been issued over 397 patents including 49 US and 21 Canadian patents as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus that we use in our clinical trial program including a composition of matter patent that expires in 2028. Our patent portfolio also includes methods for treating proliferative disorders using modified adenovirus, HSV, parapoxvirus and vaccinia virus.

Financing Activity

Common Stock Purchase Agreement

On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC"). Subject to the terms and conditions of the Agreement and at our sole discretion, we may sell up to US$26.0 million worth of common shares to LPC over the 30-month term. The purchase price of the common shares will be based on prevailing market prices of our common shares immediately preceding the notice of sale without any fixed discount. Subject to the Agreement, we control the timing and amount of any future investment and LPC is obligated to make such purchases, if and when we elect. The Agreement does not impose any upper price limit restrictions, negative covenants or restrictions on our future financing activities. We can terminate the Agreement at any time at our sole discretion without any monetary cost or penalty.

Upon signing of the Agreement, LPC purchased 248,762 common shares for gross proceeds of US$1.0 million. We issued an initial commitment fee of 110,754 common shares to LPC valued at fair value of US$455,000. An additional 110,754 common shares will be issued on a pro rata basis under the terms of the Agreement as an additional commitment fee. We issued 4,260 additional commitment fee common shares valued at fair value of US$17,501. The initial commitment fee and additional commitment fee common shares were recorded as share issue costs in addition to cash share issue costs of $151,139.

Options

During the third quarter of 2018, we received cash proceeds of $87,777 with respect to the exercise of 30,119 options by former employees.

Post Third Quarter 2018 Development

On October 24, 2018, we entered into an "at-the-Market" ("ATM") equity offering sales agreement with Canaccord Genuity Inc. The ATM allows us, at our sole discretion, to issue common shares, at prevailing market price, with an aggregate offering value of up to US$30.0 million over the next 19 months through the facilities of the NASDAQ in the United States.

Financial Impact

We estimated at the beginning of the second quarter of 2018 that our cash requirements to fund our operations for the year will be between $14 - $16 million. We now expect our cash requirements for 2018 to be between $15 - $16 million depending on our ultimate clinical program. Our cash usage for the nine month period ending September 30, 2018 was $7,526,109 for operating activities and $120,156 for the acquisition of property and equipment. Our net loss for the period was $12,217,979.

Cash Resources

We exited the third quarter of 2018 with cash and cash equivalents totaling $16,214,347 (see *"Liquidity and Capital Resources")*.

Pelareorep Development for the Remainder of 2018

Our planned 2018 development activity for pelareorep focuses on our clinical development plan along with our manufacturing and intellectual property programs. For the remainder of 2018, our clinical objective is to incorporate our immuno-oncology combination strategy that includes checkpoint inhibitors, targeted therapies and other anti-cancer agents as we finalize our registration strategy and clinical protocol in preparation for a phase 3 clinical study in mBC. We expect to commence clinical trial site selection and initiation activities and first patient enrollment in our combination studies with Tecentriq®, Keytruda® and Opdivo®. Our expectation is that these combination studies will assist us in refining our phase 3 protocol for mBC and may also support further development around the innate and adaptive immunity components of the mechanism of action.

Our 2018 manufacturing program includes preparation for continued production of 100-litre cGMP batches along with the related analytical testing and product filling, as well as labeling, packaging and shipping of pelareorep to our various clinical sites for ongoing and upcoming activities. These actions also contribute to progression through our process validation master plan. Finally, our intellectual property program includes filings for additional patents along with monitoring activities required to protect our patent portfolio.

Third Quarter Results of Operations

(for the three months ended September 30, 2018 and 2017)

Net loss for the three month period ended September 30, 2018 was $3,335,866 compared to $3,004,406 for the three month period ended September 30, 2017.

Research and Development Expenses ("R&D")

	2018 $	**2017 $**
Clinical trial expenses	**465,634**	604,503
Manufacturing and related process development expenses	**352,506**	367,513
Intellectual property expenses	**224,030**	246,373
Research collaboration expenses	**40,888**	35,564
Other R&D expenses	**563,401**	544,851
Foreign exchange loss (gain)	**174,986**	(128,835)
Share based payments	**107,960**	56,757
Research and development expenses	**1,929,405**	1,726,726

Clinical Trial Expenses

	2018 $	2017 $
Clinical trial expenses	**465,634**	604,503

Our clinical trial expenses for the third quarter of 2018 were $465,634 compared to $604,503 for the third quarter of 2017. In the third quarter of 2018, our clinical activities mainly related to closing out certain fully enrolled clinical trials and the migration and conversion of our safety data. We also incurred expenses related to updating our supporting regulatory documents and regulatory consulting activities connected to our combination studies. In the third quarter of 2017, our clinical trial program focused mainly on the preparation and development of our breast cancer registration study. These activities included costs to complete our supporting regulatory documents, regulatory filing fees, attending an End of Phase 2 meeting with the FDA and key opinion leader activities.

Manufacturing & Related Process Development Expenses ("M&P")

	2018 $	2017 $
Product manufacturing expenses	**193,159**	179,521
Process development expenses	**159,347**	187,992
Manufacturing and related process development expenses	**352,506**	367,513

Our M&P expenses for the third quarter of 2018 were $352,506 compared to $367,513 for the third quarter of 2017. During the third quarter of 2018, our product manufacturing costs included shipping and storage costs of our bulk and vialed product along with relabeling activities in line with extended stability data. During the third quarter of 2017, our product manufacturing costs mainly related to shipping and storage costs of our bulk and vialed product along with lot release testing.

Our process development expenses for the third quarter of 2018 focused on analytical development and transfer and stability studies and in the third quarter of 2017 focused on stability studies.

Intellectual Property Expenses

	2018 $	2017 $
Intellectual property expenses	**224,030**	246,373

Our intellectual property expenses for the third quarter of 2018 were $224,030 compared to $246,373 for the third quarter of 2017. The change in intellectual property expenditures reflects the timing of filing costs associated with our patent base. At the end of the third quarter of 2018, we had been issued over 397 patents including 49 US and 21 Canadian patents, as well as issuances in other jurisdictions.

Research Collaboration Expenses

	2018 $	2017 $
Research collaboration expenses	**40,888**	35,564

Our research collaboration expenses were $40,888 for the third quarter of 2018 compared to $35,564 for the third quarter of 2017. Our research collaborations during the third quarters of 2018 and 2017 included biomarker studies and studies investigating the interaction of the immune system and pelareorep.

Other Research and Development Expenses

	2018 $	2017 $
R&D salaries and benefits	**520,492**	482,855
Other R&D expenses	**42,909**	61,996
Other research and development expenses	**563,401**	544,851

Our other research and development expenses were $563,401 for the third quarter of 2018 compared to $544,851 for the third quarter of 2017. The change in our R&D salaries and benefits was mainly due to additions of U.S. headcount as we expand our U.S. operations. The change in our Other R&D expenses was due to a decrease in meeting attendance and related travel expenses.

Foreign Exchange Loss (Gain)

	2018 $	2017 $
Foreign exchange loss (gain)	**174,986**	(128,835)

Our foreign exchange loss was $174,986 for the third quarter of 2018 compared to a gain of $128,835 for the third quarter of 2017.
The change in foreign exchange loss (gain) was mainly due to unrealized translation losses or gains on U.S. dollar denominated cash balances.

Share Based Payments

	2018 $	2017 $
Share based payments	**107,960**	56,757

Non-cash share based payment expenses for the third quarter of 2018 were $107,960 compared to $56,757 for the third quarter of 2017. We incurred share based payment expenses associated with the granting of options to officers, employees and consultants associated with our research and development activities and the vesting of previously granted options and share awards.

Operating Expenses

	2018 $	2017 $
Public company related expenses	**477,994**	546,754
Office expenses	**834,923**	650,572
Depreciation of property and equipment	**26,698**	20,591
Share based payments	**128,647**	91,690
Operating expenses	**1,468,262**	1,309,607

Our operating expenses for the third quarter of 2018 were $1,468,262 compared to $1,309,607 for the third quarter of 2017. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our Canadian and U.S. stock listings. Our public company related expenses were $477,994 for the third quarter of 2018 compared to $546,754 for the third quarter of 2017. The change in our public company related expenses in the third quarter of 2018 was due to a decrease in expenses related to business development activities offset by an increase in insurance premiums as a result of the Nasdaq listing.

Office expenses include compensation costs (excluding share based payments), office rent and other office related costs. During the third quarter of 2018, our office expenses were $834,923 compared to $650,572 for the third quarter of 2017. The change was mainly due to an increase in office expenses related to the relocation of our U.S. office and an increase in headcount as we invest in the expansion of our U.S. operations in support of our clinical development program.

Non-cash share based payment expenses in the third quarter of 2018 were $128,647 compared to $91,690 in the third quarter of 2017. We incurred share based payment expenses associated with the granting of options to officers and employees and the vesting of previously granted options and share awards.

Results of Operations

(for the nine month period ending September 30, 2018 and 2017)

Net loss for the nine month period ending September 30, 2018 was $12,217,979 compared to $10,871,267 for the nine month period ending September 30, 2017.

Research and Development Expenses ("R&D")

	2018 $	2017 $
Clinical trial expenses	**2,311,934**	2,016,034
Manufacturing and related process development expenses	**1,211,275**	1,242,545
Intellectual property expenditures	**814,257**	742,458
Research collaboration expenses	**268,616**	178,516
Other R&D expenses	**1,974,677**	2,727,092
Foreign exchange gain	**(109,515)**	(176,035)
Share based payments	**438,469**	182,860
Research and development expenses	**6,909,713**	6,913,470

Clinical Trial Expenses

	2018 $	2017 $
Clinical trial expenses	**2,311,934**	2,016,034

Our clinical trial expenses were $2,311,934 for the nine month period ending September 30, 2018 compared to $2,016,034 for the nine month period ending September 30, 2017. Our clinical trial activities related primarily to the preparation and development of our breast cancer registration study. During the nine month period ending September 30, 2018, these costs included phase 3 development activities and activities related to obtaining the Special Protocol Assessment from the FDA. We also incurred expenses related to updating our supporting regulatory documents and regulatory consulting activities connected to our combination studies. In the nine month period ending September 30, 2017 included costs to complete our supporting regulatory documents, regulatory filing fees, planning for and attending an End of Phase 2 meeting with the FDA and key opinion leader activities.

We still expect our clinical trial expenses to increase in 2018 compared to 2017. For the remainder of 2018, we expect to commence clinical trial site selection and initiation activities and first patient enrollment in our combination studies with Tecentriq®, Keytruda® and Opdivo® as we refine our registration strategy and clinical protocol in preparation for a phase 3 clinical study in mBC.

Manufacturing & Related Process Development ("M&P")

	2018 $	2017 $
Product manufacturing expenses	**830,471**	828,350
Process development expenses	**380,804**	414,195
Manufacturing and related process development expenses	**1,211,275**	1,242,545

Our M&P expenses for the nine month period ending September 30, 2018 were $1,211,275 compared to $1,242,545 for the nine month period ending September 30, 2017. During the nine month period ending September 30, 2018, our product manufacturing costs included shipping and storage costs of our bulk and vialed product along with startup costs for a product fill required to support our clinical development plan. We were able to partly offset these costs by entering into a contract with a new storage depot with lower fees. We also incurred costs related to relabeling activities in line with extended stability data. During the nine month period ending September 30, 2017, our product manufacturing activities mainly related to shipping and storage costs of our bulk and vialed product.

Our process development expenses for the nine month period ending September 30, 2018 were $380,804 compared to $414,195 for the nine month period ending September 30, 2017. During the nine month period ending September 30, 2018, our process development activities focused on analytic development and stability studies. During the nine month period ending September 30, 2017, our activities focused on stability studies.

We still expect our M&P expenses for 2018 to increase compared to 2017. In 2018, we expect to label and store sufficient product as we commence enrollment in our clinical development program and produce sufficient supply to support our registration efforts in breast cancer. We also expect to continue to perform stability testing and analytical development related to our process validation master plan.

Intellectual Property Expenses

	2018 $	2017 $
Intellectual property expenses	**814,257**	742,458

Our intellectual property expenses for the nine month period ending September 30, 2018 were $814,257 compared to $742,458 for the nine month period ending September 30, 2017. The change in intellectual property expenditures reflects the timing of filing costs associated with our patent base. At the end of the nine month period ending September 30, 2018, we had been issued over 397 patents including 49 U.S. and 21 Canadian patents, as well as issuances in other jurisdictions.

We still expect that our intellectual property expenses will remain consistent in 2018 compared to 2017.

Research Collaborations

	2018 $	2017 $
Research collaborations	**268,616**	178,516

Our research collaboration expenses for the nine month period ending September 30, 2018 were $268,616 compared to $178,516 for the nine month period ending September 30, 2017. During the nine month periods ending September 30, 2018 and 2017, our research collaborations included biomarker studies and studies investigating the interaction of the immune system and pelareorep.

We still expect that our research collaborations in 2018 will increase compared to 2017. We expect to complete our ongoing collaborative program carried over from 2017 and will continue to be selective in the types of new collaborations we enter into in 2018.

Other Research and Development Expenses

	2018 $	2017 $
R&D salaries and benefits	**1,821,362**	2,542,104
Other R&D expenses	**153,315**	184,988
Other research and development expenses	**1,974,677**	2,727,092

Our Other Research and Development expenses for the nine month period ending September 30, 2018 were $1,974,677 compared to $2,727,092 for the nine month period ending September 30, 2017. The change in our R&D salaries and benefits was mainly due to severance payments to certain officers of the Company who were terminated during the second quarter of 2017. The change in our Other R&D expenses was due to a decrease in meeting attendance and related travel expenses.

We now expect our Other R&D expenses to be lower in 2018 compared to 2017.

Foreign Exchange Gain

	2018 $	2017 $
Foreign exchange gain	**(109,515)**	(176,035)

Our foreign exchange gain for the nine month period ending September 30, 2018 was $109,515 compared to $176,035 for the nine month period ending September 30, 2017. The change in foreign exchange gain was mainly due to unrealized translation gains on U.S. dollar denominated cash balances.

Share Based Payments

	2018 $	2017 $
Share based payments	**438,469**	182,860

During the nine month period ending September 30, 2018, our non-cash share based payment expenses were $438,469 compared to $182,860 for the nine month period ending September 30, 2017. We incurred share based payment expenses associated with the granting of options and share awards to officers, employees and consultants associated with our research and development activities and the vesting of previously granted options and share awards. In the second quarter of 2018, we also recognized a recovery of share based payment expenses due to the departure of the Chief Medical Officer and the forfeiture of unvested share awards and options. We granted 212,855 options and share awards in the nine month period ending September 30, 2018 compared to 6,840 options and share awards in the nine month period ending September 30, 2017.

Operating Expenses

	2018 $	2017 $
Public company related expenses	**2,043,724**	2,001,689
Office expenses	**2,263,863**	1,727,262
Amortization of property and equipment	**67,682**	70,315
Share based payments	**494,348**	255,184
Operating expenses	**4,869,617**	4,054,450

Our operating expenses for the nine month period ending September 30, 2018 were $4,869,617 compared to $4,054,450 for the nine month period ending September 30, 2017. Public company related expenses include costs associated with investor relations, business development and financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent and other fees relating to our U.S. and Canadian stock listings. During the nine month period ending September 30, 2018, our public company related expenses were $2,043,724 compared to $2,001,689 for the nine month period ending September 30, 2017. The change was due to an increase in expenses related to the Nasdaq listing, an increase in legal fees and costs related to the special meeting of shareholders held in February 2018 and an increase in travel expenses, partly offset by a decrease in professional fees.

Office expenses include compensation costs (excluding share based payments), office rent, and other office related costs. During the nine month period ending September 30, 2018, we incurred office expenses of $2,263,863 compared to $1,727,262 during the nine month period ending September 30, 2017. The change was mainly due to an investment in our business development department and an increase in office expenses related to the opening and relocation of our U.S. office.

During the nine month period ending September 30, 2018, our non-cash share based payment expenses were $494,348 compared to $255,184 for the nine month period ending September 30, 2017. We incurred share based payment expenses associated with the granting of stock options to officers and employees and the vesting of previously granted options and share awards. We granted 123,503 options and share awards in the nine month period ending September 30, 2018 compared to 52,117 options and share awards in the nine month period ending September 30, 2017.

We still expect our operating expenses in 2018 to increase compared to 2017.

Commitments

As at September 30, 2018, we are committed to payments totaling approximately $5,850,832 for activities related to our clinical trial, manufacturing and collaboration programs which are expected to occur over the next two years. We are committed to rental payments (excluding our portion of operating costs and rental taxes) under the terms of our office leases totaling $1,025,595 for 2018 to 2021. In the third quarter of 2018, we entered into a new multi-year lease agreement which provided for lease incentives of $77,911 to be recognized over the lease term. We also recorded an onerous lease provision related to the old lease of $67,588 as a result of this lease agreement. All of these committed payments are considered to be part of our normal course of business.

Summary of Quarterly Results

	2018				2017			2016
	Sept	June	Mar	Dec	Sept	June	Mar	Dec
Revenue	—	—	—	—	—	—	—	—
Net loss[2]	3,336	4,211	4,671	4,746	3,004	4,349	3,518	5,210
Basic and diluted loss per common share[2]	$ 0.20	$ 0.27	$ 0.31	$ 0.32	$ 0.20	$ 0.32	$ 0.28	$ 0.41
Total assets[3]	18,150	20,693	14,127	18,150	14,848	17,579	10,623	14,758
Total cash[1], [3]	16,214	18,741	7,745	11,836	14,034	16,676	10,102	14,123
Total long-term debt	—	—	—	—	—	—	—	—
Cash dividends declared[4]	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil

(1) Included in total cash are cash and cash equivalents plus short-term investments.

(2) The calculation of basic and diluted loss per common share for all periods has been adjusted retrospectively for the Share Consolidation. Included in net loss and loss per common share between September 2018 and October 2016 are quarterly share based payment expenses of $236,607, $157,092, $539,118, $140,659, $148,447, $155,708, $133,889, and $106,443, respectively.

(3) We issued 590,500 pre-consolidation common shares (approximately 62,157 post-consolidation common shares) for net cash proceeds of $0.5 million and 1,926,330 post-consolidation common shares for net cash proceeds of $11.5 million in 2018 (2017 - 20,547,500 pre-consolidation common shares (approximately 2,162,894 post-consolidation common shares) for net cash proceeds of $12.8 million).

(4) We have not declared or paid any dividends since incorporation.

Liquidity and Capital Resources

2018 Financing Activities

Share Consolidation

On May 22, 2018, we completed a consolidation of our common shares on the basis of 9.5 pre-consolidation common shares for each one post-consolidation common share (the "Share Consolidation"). Fractional interests were rounded down to the nearest whole number of common shares. Outstanding stock options, restricted share units and performance share units were similarly adjusted by the consolidation ratio. Outstanding warrants were adjusted such that, following the Share Consolidation, 9.5 pre-consolidation warrants entitle the holder to purchase one post-consolidation common share until June 1, 2022.

Listing on the Nasdaq Capital Market

On June 1, 2018, we announced that our common shares were approved for listing and commenced trading on the Nasdaq Capital Market.

Public offering

On June 5, 2018, we closed a public offering whereby we sold 1,532,278 post-consolidation common shares at a purchase price of US$5.83 per share for gross proceeds of US$8,933,181. We incurred share issue costs of $1,418,356.

Common Stock Purchase Agreement

On September 27, 2018, we entered into a Common Stock Purchase Agreement (the "Agreement") with Lincoln Park Capital Fund, LLC ("LPC") to sell up to US$26.0 million of common stock. Upon signing of the Agreement, LPC purchased 248,762 common shares for gross proceeds of US$1.0 million. We issued an initial commitment fee of 110,754 common shares to LPC valued at fair value of US$455,000. An additional 110,754 common shares will be issued on a pro rata basis under the terms of the Agreement as an additional commitment fee. We issued 4,260 additional commitment fee common shares valued at fair value of US$17,501. The initial commitment fee and additional commitment fee common shares were recorded as share issue costs in addition to cash share issue costs of $151,139.

Canadian "At-the-Market" equity distribution agreement
In the first quarter of 2018, we sold 519,500 pre-consolidation common shares (approximately 54,684 post-consolidation common shares) for net proceeds of $520,315.

Options
During the nine month period ending September 30, 2018, we received cash proceeds of $111,687 with respect to the exercise of 37,592 post-consolidation options (approximately 357,130 pre-consolidation options) by former employees.

Warrants
During the nine month period ending September 30, 2018, we received cash proceeds of $1,417 with respect to the exercise of 1,500 warrants.

2017 Financing Activities

Canadian "At-the-Market" equity distribution agreement
During the nine month period ending September 30, 2017, we sold 2,167,500 pre-consolidation common shares (approximately 228,157 post-consolidation common shares) for gross proceeds of $1,479,065. We incurred share issue costs of $186,367.

Public offering
On June 1, 2017, pursuant to an underwritten public offering, 16,445,000 units were sold at a purchase price of $0.70 per unit for gross proceeds of $11,511,500. Each unit included one pre-consolidation common share (0.106 post-consolidation common share) and one common share purchase warrant. Following the Share Consolidation, 9.5 common share purchase warrants entitle the holder to purchase one common share in the capital of the Company until June 1, 2022, at an exercise price of approximately $9.025. The post-consolidation common share purchase warrants will be subject to acceleration if the volume weighted average price of the Company's common shares equals or exceeds $23.75 for 15 consecutive trading dates. We incurred share issue costs of $1,145,402.

Options
During the nine month period ending September 30, 2017, we received cash proceeds of $343,440 with respect to the exercise of 801,000 pre-consolidation options (approximately 84,315 post-consolidation options) by former employees.

Liquidity

As at September 30, 2018, we had cash and cash equivalents and working capital positions as follows:

	September 30, 2018 $	**December 31, 2017 $**
Cash and cash equivalents	**16,214,347**	11,836,119
Working capital position	**14,477,829**	12,587,340

We do not have any debt other than trade accounts payable and we have potential contingent obligations relating to the completion of our research and development of pelareorep.

In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the costs associated with these activities. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year’s activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.

Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares. Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital. There are no assurances that funds will be made available to us when required.

On May 4, 2018, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to 150,000,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the US or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents or other intermediaries and also may

sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be effected from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.

Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time period required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in our company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until May 25, 2020.

Our Base Shelf allowed us to enter into our Common Stock Purchase Agreement in the third quarter of 2018 (see Note 5 of our interim consolidated financial statements) and our ATM equity offering sales agreement in October 2018 (see Note 15 of our interim financial statements). We will use these equity arrangements to assist us in achieving our capital objective. Each arrangement provides us with the opportunity to raise capital at our sole discretion providing us with the ability to better manage our cash resources.

We anticipate that the expected cash usage from our operations in 2018 will be between $15 - $16 million. We continue to manage our research and development plan with the objective of ensuring optimal use of our existing resources. Additional activities continue to be subject to adequate resources and we believe we will have sufficient cash resources to fund our presently planned operations to the end of 2018. Factors that will affect our anticipated cash usage in 2018, and for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our approved clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, and the level of collaborative activity undertaken.

We are not subject to externally imposed capital requirements and there have been no changes in how we define or manage our capital in 2018.

Financial Instruments and Other Instruments

Our financial instruments consist of cash and cash equivalents, other receivables and accounts payable. As at September 30, 2018, there are no significant differences between the carrying values of these amounts and their estimated market values. These financial instruments expose us to the following risks:

Credit risk
Credit risk is the risk of financial loss if a counter-party to a financial instrument fails to meet its contractual obligations. We are exposed to credit risk on our cash and cash equivalents and contract receivable in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents and contract receivable.

We mitigate our exposure to credit risk by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada. For our foreign domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts and these accounts are used solely for the purpose of settling accounts payable or payroll.

Interest rate risk
Interest rate risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in market interest rates. We are exposed to interest rate risk through our cash and cash equivalents and our portfolio of short-term investments. We mitigate this risk through our investment policy that only allows investment of excess cash resources in investment grade vehicles while matching maturities with our operational requirements.

Fluctuations in market rates of interest do not have a significant impact on our results of operations due to the short term to maturity of the investments held.

Currency risk
Currency risk is the risk that future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. In the normal course of our operations, we are exposed to currency risk from the purchase of goods and services primarily in the U.S., the U.K. and the European Union. In addition, we are exposed to currency risk to the extent cash is held in foreign currencies from either the purchase of foreign currencies or when we receive foreign currency proceeds from operating and financing activities. As well, we are exposed to currency risk related to our regional licensing agreement. The impact of a $0.01

increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net loss in 2018 by approximately $54,035. The impact of a $0.10 increase in the value of the British pound against the Canadian dollar would have increased our net loss in 2018 by approximately $21,923. The impact of a $0.10 increase in the value of the Euro against the Canadian dollar would have increased our net loss in 2018 by approximately $8,978.

We mitigate our foreign exchange risk by maintaining sufficient foreign currencies, through the purchase of foreign currencies or receiving foreign currencies from financing activities, to settle our foreign accounts payable.

Balances in foreign currencies at September 30, 2018 are as follows:

	US dollars $	**British pounds £**	**Euro €**
Cash and cash equivalents	11,123,553	23,827	24,246
Accounts payable	(430,913)	(46,510)	—
	10,692,640	(22,683)	24,246

Liquidity risk
Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in Note 10 of our interim consolidated financial statements. Accounts payable are all due within the current operating period.

Other MD&A Requirements

We have 17,059,123 common shares outstanding at November 8, 2018. If all of our options, restricted share units and performance share units (1,093,407) and common share purchase warrants (1,730,894) were exercised or were to vest, we would have 19,883,424 common shares outstanding.

Our 2017 annual report on Form 20-F is available on www.sedar.com.

Disclosure Controls and Procedures

There were no changes in our internal controls over financial reporting during the quarter ended September 30, 2018 that materially affected or are reasonably likely to materially affect, our internal controls over financial reporting.

FORM 52-109F2
CERTIFICATION OF INTERIM FILINGS
FULL CERTIFICATE

I, Matthew Coffey, President and CEO of Oncolytics Biotech Inc., certify the following:

1. ***Review:*** I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Oncolytics Biotech Inc. (the "issuer") for the interim period ended September 30, 2018.

2. ***No misrepresentations:*** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. ***Fair presentation:*** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. ***Responsibility:*** The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in *National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings*, for the issuer.

5. ***Design:*** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings:

   (a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that:

      (i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

      (ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

   (b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 ***Control framework:*** The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 ***ICFR - material weakness relating to design:***
N/A.

5.3 ***Limitation on scope of design:***
N/A.

6. ***Reporting changes in ICFR:*** The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on January 1, 2018 and ended on September 30, 2018 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: November 12, 2018

/s/ Matthew Coffey

Matthew Coffey Ph.D., M.B.A.
President and CEO

FORM 52-109F2
CERTIFICATION OF INTERIM FILINGS
FULL CERTIFICATE

I, Kirk Look, CFO of Oncolytics Biotech Inc., certify the following:

1. ***Review:*** I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Oncolytics Biotech Inc. (the "issuer") for the interim period ended September 30, 2018.

2. ***No misrepresentations:*** Based on my knowledge, having exercised reasonable diligence, the interim filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the interim filings.

3. ***Fair presentation:*** Based on my knowledge, having exercised reasonable diligence, the interim financial report together with the other financial information included in the interim filings fairly present in all material respects the financial condition, financial performance and cash flows of the issuer, as of the date of and for the periods presented in the interim filings.

4. ***Responsibility:*** The issuer's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (DC&P) and internal control over financial reporting (ICFR), as those terms are defined in *National Instrument 52-109 Certification of Disclosure in Issuers' Annual and Interim Filings*, for the issuer.

5. ***Design:*** Subject to the limitations, if any, described in paragraphs 5.2 and 5.3, the issuer's other certifying officer(s) and I have, as at the end of the period covered by the interim filings:

   (a) designed DC&P, or caused it to be designed under our supervision, to provide reasonable assurance that:

      (i) material information relating to the issuer is made known to us by others, particularly during the period in which the interim filings are being prepared; and

      (ii) information required to be disclosed by the issuer in its annual filings, interim filings or other reports filed or submitted by it under securities legislation is recorded, processed, summarized and reported within the time periods specified in securities legislation; and

   (b) designed ICFR, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuer's GAAP.

5.1 ***Control framework:*** The control framework the issuer's other certifying officer and I used to design the issuer's ICFR is the Internal Control -- Integrated Framework (2013) published by The Committee of Sponsoring Organizations of the Treadway Commission (COSO).

5.2 ***ICFR - material weakness relating to design:***
N/A.

5.3 ***Limitation on scope of design:***
N/A.

6. ***Reporting changes in ICFR:*** The issuer has disclosed in its interim MD&A any change in the issuer's ICFR that occurred during the period beginning on January 1, 2018 and ended on September 30, 2018 that has materially affected, or is reasonably likely to materially affect, the issuer's ICFR.

Date: November 12, 2018

/s/ Kirk Look

Kirk Look, CA
CFO